Dr. Reddy's

Biosimilars at scale — affordable biosimilar mAbs.

Country
India
biosimilars in
Coverage
CNEUINUS
therapeutics-platforms✓✓✓✓
Regulatorsfdaemanmpa

Verifiable facts

FactValueSource
RevenueUS$ 3.8 billion for fiscal year 2025drreddys.com
Headcount26,944 employees globally as of March 31, 2025drreddys.com
Capacity12 million vials and 18 million pre-filled syringes annually for biosimilarsdrreddysbiologics.com
Production siteHyderabad, India, including a cutting-edge biologics CDMO facility in Genome Valleyrisecorp.co.in · drreddysbiologics.com
Certification19 manufacturing facilities are ISO 45001 certified; facilities meet global quality standards with accreditations from regulatory bodies across Europe, Latin America, and other international marketsdrreddys.com · drreddysbiologics.com
Regulatory approvalReceived marketing authorisation for rituximab biosimilar in Europe (EMA) and UK (MHRA); BLA for denosumab biosimilar accepted by US FDAdrreddys.com · drreddysbiologics.com · sec.gov
FundingThe company invests approximately 8-10% of its annual revenues in R&D, with specific focus on building its biosimilars pipeline; a ₹10,000 crore national initiative (Biopharma SHAKTI) was launched in the Union Budget 2026 to strengthen India's biologics manufacturing ecosystem medium confidenceeconomictimes.indiatimes.com · drreddys.com

Independent sources: economictimes.indiatimes.com · risecorp.co.in · sec.gov

Technologies
NameClusterRisk
Biopharmaceuticals & biomedicinestherapeutics-platformsLow→

Compiled by BIOECON from primary sources.

Compliance Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.